# The impact of diversity on Alzheimer's disease clinical trial design 18 Oct 23 news # The impact of diversity on Alzheimer's disease clinical trial design John Dwyer Lammert Albers Robin Wolz Alzheimer's disease amyloid PET PET diversity in clinical trials [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/the-impact-of-diversity-on-alzheimers-disease-clinical-trial-design/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/the-impact-of-diversity-on-alzheimers-disease-clinical-trial-design/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/the-impact-of-diversity-on-alzheimers-disease-clinical-trial-design/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/the-impact-of-diversity-on-alzheimers-disease-clinical-trial-design/) ![GAP + IXICO Diversity in AD Clinical Trials Final Oct 2023 cover v2](/assets/blog-images/GAP-+-IXICO-Diversity-in-AD-Clinical-Trials-Final-Oct-2023-cover-v2__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp)"We saw the explosion of need that was going to occur with the approval of disease-modifying therapy, and this was back in 2020. And we knew that the healthcare system and the clinical trial system needed to get more sophisticated with the way in which it conducted its proces ses to provide better assessments and diagnoses of disease with higher reliability" With momentum gaining in Alzheimer’s disease treatment following multiple approvals for new drugs to treat patients, the spotlight turns towards other avenues of investment to propel our understanding of this devastating disease. Results from the recent GAP Bio-Hermes study show a clear area of opportunity for better understanding: patient diversity. [Lammert Albers](https://www.linkedin.com/in/ACoAAAAFoH4BKSG2T29QOF14LvFJJ6NMB2B2m0g), Chief Commercial Officer of the [Global Alzheimer's Platform Foundation](https://www.linkedin.com/company/global-alzheimers-platform-foundation/) talks with [John Dwyer](https://www.linkedin.com/in/ACoAAARaizMBbxnHkUu8rhL7jFbTZ6Op8z1_Aws), President of the foundation, and our Chief Scientific Officer, [Robin Wolz](https://www.linkedin.com/in/ACoAAAGzgHAB-wuSYXmHIJwL1X4clmp3vtomgtc) about the impact of this study diversity on current and future research and the opportunities at hand. At the upcoming [CTAD Clinical Trials on Alzheimer's Disease](https://www.linkedin.com/company/ctad-congress/) 2023 conference in Boston, Robin will be presenting a symposium on the topic. **Symposium 1 Details:** Presentation 1: Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups Date: Tuesday, October 24th 2023 Time: 4:55pm Location: Grand Ballroom AB For inquiries on this presentation, our collaborative efforts with the Global Alzheimer's Platform Foundation or if you'd like to meet with us at CTAD 2023, please reach out to . In-person registrations are sold out for CTAD 2023, but you can still purchase a digital registration so you don't miss out on the content. Please visit the [CTAD registration website](https://www.ctad-alzheimer.com/registrations-1) for more details [ Back to News ](/news-and-resources/news/) ### Recents ![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 2 Nov 26 news [IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/) [IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/) [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) ### Library [November 2026](/news-and-resources/news/archive/2026/11/) [October 2026](/news-and-resources/news/archive/2026/10/) [September 2026](/news-and-resources/news/archive/2026/09/) [July 2026](/news-and-resources/news/archive/2026/07/) [June 2026](/news-and-resources/news/archive/2026/06/) [May 2026](/news-and-resources/news/archive/2026/05/) [April 2026](/news-and-resources/news/archive/2026/04/) [March 2026](/news-and-resources/news/archive/2026/03/) [February 2026](/news-and-resources/news/archive/2026/02/) [January 2026](/news-and-resources/news/archive/2026/01/) [2025](/news-and-resources/news/archive/2025/) [2024](/news-and-resources/news/archive/2024/) [2023](/news-and-resources/news/archive/2023/) [2022](/news-and-resources/news/archive/2022/) [2021](/news-and-resources/news/archive/2021/) [2020](/news-and-resources/news/archive/2020/) [2019](/news-and-resources/news/archive/2019/)